Stock screenerAll disclosures →
EDGAR →
NUVB
Conviction 62HealthcareScan · Mon, Aug 10, 2026NUVB$6.62+0.23%
ResistanceSupportVol 14Insider sellVol MA14 5.99M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price6.62
Change+0.23%
Gap+0.00%
Rel volume1.22×
Avg volume6.14M
Avg $ vol38.95M
SMA 206.33
SMA 505.76
SMA 2005.78
Price vs 50+14.80%
Price vs 200+14.43%
MA stackmixed
50/200 cross—
Supertrendup · 5.44
RSI (14)59
MACD hist-0.03
MACD crossbear · 5d
Stoch %K / %D77 / 59
ADX (14)23
+DI / −DI17 / 18
RSI divergence—
MACD divergence—
ATR %+5.93%
ADR %5.99%
52w high9.54
52w low2.24
From 52w high-30.66%
Above 52w low+195.31%
New 52w highNo
SqueezeOff
Bollinger width19.53%
%B0.73
Donchian pos87.63%
Donchian high6.80
Donchian low5.34
AVWAP (52w high)5.68
vs AVWAP high+16.36%
AVWAP (52w low)5.35
vs AVWAP low+23.72%
OBV trendUp
Chaikin MF (20)0.12
Today vs 20d1.22×
Avg vol (14d)5.99M
Avg vol (20d)6.14M
Avg $ vol (20d)38.95M
Market cap2.32B
RS 3m (vs SPY)+31.52%
RS 6m (vs SPY)+3.32%
RS line new highNo
Trend template5/8
Technical rank82.1
1 week+7.39%
1 month+13.86%
3 months+38.10%
6 months+16.05%
1 year+182.69%
YTD-22.90%
P/E-11.35
P/B9.15
P/S36.93
P/FCF—
EPS-0.6000
Div yield—
ROE-80.61%
ROA-27.48%
Debt/Eq0.98
Current8.37
EV/EBITDA-10.94
Gross margin1.26%
Net margin-325.31%
Rev growth698.96%
EPS growth63.97%
Price target15.17
Target upside129.33%
Analyst ratingBuy
Institutional68.58%
Ent. value2.31B
Revenue31.69M
Net income-62.84M
Gross profit9.77M
Free cash flow—
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNYSE
Shares out348.2M
Employees307
ListedWed, Feb 10, 2021
Free float236.38M
Float %69.0%
Short interest55.67M
Days to cover8.0d
Short volume61.7%
Squeeze score83 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.15 vs −$0.15
Last surprise0.0% beat
Setup gradeB
Conviction62 / 100
Pattern quality—
Tech rank82.1 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance6.71
Support5.34
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in NUVB
No recent disclosed trades by Congress in NUVB. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in NUVB · 8 buys · 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Sauvage Philippe Chief Financial Officer · Stock Option (Right to Buy) · 2026-07-15 | Exercise | 1 | — | 2026-07-15 | 2026-07-17 |
Sauvage Philippe Chief Financial Officer · Class A Common Stock · 2026-07-15 | Exercise | 1 | $2 | 2026-07-15 | 2026-07-17 |
Sauvage Philippe Chief Financial Officer · Class A Common Stock · 2026-07-15 | Exercise | 40K | $87K | 2026-07-15 | 2026-07-17 |
Sauvage Philippe Chief Financial Officer · Stock Option (Right to Buy) · 2026-07-15 | Exercise | 40K | — | 2026-07-15 | 2026-07-17 |
Bazemore Robert B Director · Stock Option (Right to Buy) · 2026-05-21 | Grant | 123.4K | $0 | 2026-05-21 | 2026-05-26 |
FALBERG KATHRYN E Director · Stock Option (Right to Buy) · 2026-05-21 | Grant | 123.4K | $0 | 2026-05-21 | 2026-05-26 |
Cui Xiangmin Director · Stock Option (Right to Buy) · 2026-05-21 | Grant | 123.4K | $0 | 2026-05-21 | 2026-05-26 |
BLICKENSTAFF KIM D Director · Stock Option (Right to Buy) · 2026-05-21 | Grant | 123.4K | $0 | 2026-05-21 | 2026-05-26 |
Mashal Robert Director · Stock Option (Right to Buy) · 2026-05-21 | Grant | 123.4K | $0 | 2026-05-21 | 2026-05-26 |
VERNON W ANTHONY Director · Stock Option (Right to Buy) · 2026-05-21 | Grant | 123.4K | $0 | 2026-05-21 | 2026-05-26 |
SEC filings
EDGAR filings in NUVB · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.